Pandemic Perspectives: Pharma Must Not Let Its COVID-19 Halo Slip
COVID-19 Could Set A Precedent For The Biopharma Industry That Companies Will Struggle to Live Up To
Executive Summary
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.